# Pizarra — PT-pseudo_dcd7bf13a6f4 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_dcd7bf13a6f4
Task: 1

Encounter: Urology - outpatient on 25 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 6.77 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.239 ng/mL²
  - PSA velocity: 1.85 ng/mL/yr
  - Prior PSA: 4.3 ng/mL
  - Prostate volume: 28.27 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8536296 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 6.77 ng/mL. PI-RADS 5. PSAD 0.24. Prostate volume 28 mL. csPCa 0.85.

Vitals: weight 80 kg, height 171 cm, BMI 27.4, BP 133/92 mmHg, HR 72 bpm. Smoking: Current smoker (38 pack-yr).

Chief complaint: Evaluation is required given the ascending prostate-specific antigen levels and the recently completed multiparametric MRI.

History: Investigation was initiated for a progressively climbing prostate-specific antigen in this 74-year-old graphic designer. The most recent laboratory draw recorded 6.77 ng/mL, an increase from 2.6 ng/mL back in January 2024. He shares his home with his partner, stays active through twice-weekly tennis sessions, and limits alcohol intake to approximately three units per week. Severe lower urinary tract symptoms dominate his clinical picture, yielding an IPSS of 22, yet he explicitly denies hematuria, pelvic discomfort, or systemic complaints. His surgical history includes a right knee arthroscopy performed half a decade ago, while his blood pressure remains controlled without pharmacological intervention. A substantial smoking history of 38 pack-years is noted. Following a recent routine chest X-ray, he requests written documentation due to mild hearing loss that complicates rapid conversation.

Physical examination: DRE reveals a uniformly smooth gland with no focal induration, asymmetry, or palpable nodules. The subject appears well-nourished and shows no signs of acute distress. Vitals register at a blood pressure of 133/92 mmHg and a heart rate of 72 bpm. Otoscopic evaluation confirms mild bilateral hearing deficits, aligning with his stated difficulty tracking fast-paced dialogue. The remainder of the systemic survey yields unremarkable results.

Patient info: graphic designer; Married; Lives with partner.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 3 units / week; exercise Tennis 2x/week; IPSS score: 22/35 (severe LUTS).

Recent other appointments: Radiology — chest X-ray (routine).
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.88 +/- 0.11   (95% CI 0.60-1.00)

Where the uncertainty comes from:
  - aleatoric  dA = 0.10  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.04  (few labelled cases resemble this one)
  - 7.4 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=6.77, age=74.0, psad=0.239, dre_ord=0.0, vol=28.27, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the specific PSA velocity (1.85 ng/mL/yr) or the prior PSA (4.3 ng/mL), which indicate a rapid ascent, against the PI-RADS 5 and the high csPCa probability (0.8536296). It also missed the context provided by the full mpMRI report and the detailed laboratory panel, which might refine the risk stratification beyond the basic inputs.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy (0.88), but the data shows a PI-RADS 5, which is high risk, but the DRE is reported as 'Normal'. This internal contradiction between high imaging suspicion and a normal physical exam could significantly alter the decision. Furthermore, the prior does not account for the PSA velocity (1.85 ng/mL/yr) or the prior PSA (4.3 ng/mL), which suggest a significant, rapid rise, potentially overriding the PI-RADS score if the clinical trajectory is more concerning.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <laboratory results> -> <full panel> -> <If labs show elevated PSA density or other markers, it might change the risk assessment.>
  <PSA history (trend)> -> <PSA trend/velocity> -> <A more aggressive trend might push the decision towards biopsy despite the DRE.>
  <radiology / mpMRI report> -> <full mpMRI prose> -> <The detailed report might provide crucial information on the extent or nature of the lesion that influences the biopsy decision.>
  <previous GP / urology consultation notes> -> <previous notes> -> <These notes might contain context regarding the LUTS or prior management that influences the current urgency.>

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  Jeroen Bosch Ziekenhuis ('s-Hertogenbosch) | 20 Feb 2025 | multiparametric MRI prostate
  Clinical indication: PSA value of "6.77" ng/mL, prior PI-RADS "5", evaluate lesion characteristics.
  FINDINGS: Glandal volume registers at 28.27 mL. A focal abnormality sits at the left peripheral zone base-to-mid junction, spanning 12 mm in greatest dimension. T2-weighted sequences show marked hypointensity. DWI confirms restricted diffusion alongside low ADC values. DCE highlights early, focal enhancement against adjacent parenchyma. No extraprostatic extension or seminal vesicle invasion appears. Suspicious lymphadenopathy or osseous lesions remain absent.
  IMPRESSION: PI-RADS "5" lesion in the left peripheral zone. PSA density of "0.239" ng/mL/mL. csPCa predicted probability of "0.8536296".

  **PSA history**
  {"date": "Jan 2024", "val": 0.5}, {"date": "May 2024", "val": 4.0}, {"date": "Oct 2024", "val": 1.5}, {"date": "Feb 2025", "val": 6.77}

  **laboratory results**
  {"name": "PSA", "val": "6.8 ng/mL", "date": "28 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.41 ng/mL", "date": "28 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "21%", "date": "28 Jan 2025", "flag": ""}, {"name": "Haemoglobin", "val": "16.0 g/dL", "date": "28 Jan 2025", "flag": ""}, {"name": "WBC", "val": "6.4 x10^9/L", "date": "28 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "187 x10^9/L", "date": "28 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "89 umol/L", "date": "28 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "28 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "16.1 nmol/L", "date": "28 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "70 U/L", "date": "28 Jan 2025", "flag": ""}, {"name": "LDH", "val": "155 U/L", "date": "28 Jan 2025", "flag": ""}]

  **previous GP / urology consultation notes**
  {"date": "04 Sep 2023", "author": "Dr. P. van Dijk (GP)", "text": "During a routine wellness visit on 04 Sep 2023, Dr. P. van Dijk (GP) noted persistent lower urinary tract symptoms, quantified at an IPSS of 22. Laboratory work revealed a PSA reading of 3.8 ng/mL, marking a steady climb over twelve months. Physical activity remains robust with biweekly tennis matches, alongside modest alcohol consumption at three units weekly. Because of the ascending marker, a urology outpatient referral has been organized."}, {"date": "08 Mar 2023", "author": "Dr. P. van Dijk (GP)", "text": "On 08 Mar 2023, Dr. P. van Dijk (GP) conducted a monitoring session for a previously flagged PSA elevation. Recent labs returned a value of 2.9 ng/mL, resting just above the standard reference interval. The individual experiences steady urinary frequency but denies acute retention or blood in the urine. A subsequent blood draw has been planned for later in the year to monitor trends."}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision point based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion in the left peripheral zone.
  PSA velocity of 1.85 ng/mL/yr, indicating a rapid ascent.
  csPCa predicted probability of 0.8536296.
  PSA trend shows a significant rise from 4.3 ng/mL (prior) to 6.77 ng/mL (current).

  AGAINST sampling this patient now:
  DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk imaging (PI-RADS 5), the rapid PSA velocity, and the high predicted cancer probability, which overrides the normal DRE finding. This leans toward the statistical prior but is supported by specific pathological risk markers.

[Sections actually revealed in this consultation: psa_trend, radiology_report, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk imaging (PI-RADS 5 lesion) and significant clinical trajectory, evidenced by a rapid PSA velocity of 1.85 ng/mL/yr and a high csPCa predicted probability of 0.8536296. Although the DRE was normal, the combination of a PI-RADS 5 finding and a rapidly ascending PSA strongly warrants tissue sampling to clarify the diagnosis and guide management.

Variables that carried weight: age=noted, dre=noted, psa=decisive, vol=noted, psad=important, cspca=important, pirads=decisive
Sections revealed: psa_trend, radiology_report, laboratory_results, previous_notes
